Oncology Brothers: Practice-Changing Cancer Discussions

On a mission to disseminate information to the community and bridge the gap between academia and community oncology in this rapidly changing field of hematology & oncology. Drs. Rahul & Rohit Gosain interview world-renowned hematologists/oncologists to present the practice-changing data in a small bite-sized format where one could immediately apply that information in their daily practice to provide the best cancer care to their patients close to home.Privacy Policy: https://oncbrothers.com/privacy-policyTerms & Conditions: https://oncbrothers.com/terms-and-conditions

Oncology Brothers: Practice-Changing Cancer Discussions is a health podcast hosted by Oncology Brothers, with 271 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Oncology Brothers hosts Oncology Brothers: Practice-Changing Cancer Discussions, a health show with 271 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Oncology Brothers: Practice-Changing Cancer Discussions

  Managing Toxicities of Androgen Receptor Pathway Inhibitor (ARPI) in Prostate Cancer

  Aug 17, 202625 min

  Welcome to the Oncology Brothers podcast! In this episode, we discussed the world of androgen receptor pathway inhibitors (ARPIs) in prostate cancer as part of our Tox Check series. Joined by esteemed guests Dr. Alicia Morgans, a GU medical oncologist from Dana-Farber Cancer Institute, and Dr. Christopher M. Pieczonka, a urologist from US Urology Partners, the discussion covered the common side effects associated with ARPIs, including cardiac issues, cognitive changes, and more. Key topics included: An overview of approved ARPIs, focusing on abiraterone , apalutamide , darolutamide , and enzalutamide The importance of monitoring side effects and strategies to mitigate them Insights from recent studies, highlighting the impact of these medications on patient quality of life A discussion on the role of shared decision-making in treatment options for prostate cancer patients Whether you're a healthcare professional or someone interested in prostate cancer treatment, this episode aims to equip you with valuable knowledge to better manage patient care. Listen us on: Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more insightful discussions from the Oncology Brothers! #ProstateCancer, #ARPI, #SideEffectManagement, #SharedDecisionMaking, #OncologyBrothers

  ListenShow Notes
• 

  Oncology Brothers: Practice-Changing Cancer Discussions

  Challenging Cases in Myelodysplastic Syndrome (MDS) - Dr. Amer Zeidan

  Aug 13, 202625 min

  Join us with as we dive into two challenging cases of myelodysplastic syndromes (MDS) in this episode featuring Dr. Amer Zeidan, from the Yale School of Medicine. The discussion focused on real-life scenarios from community settings, exploring treatment decisions in both frontline settings and cases of disease progression. In the first case, we examined a 74-year-old gentleman with persistent anemia and discussed the implications of his diagnosis, treatment options like erythropoiesis-stimulating agents (ESAs) and luspatercept , and the importance of timely intervention. The conversation highlighted the evolving landscape of MDS treatment, including the significance of molecular risk stratification and the potential for improved patient outcomes. The second case featured a 67-year-old woman whose disease has progressed despite initial treatment with luspatercept. Dr. Zeidan shared insights on the next steps, including the use of hypomethylating agents (HMAs) , the role of transplant, and the management of side effects associated with these therapies. Tune in for an informative discussion that not only addressed treatment strategies but also emphasized the importance of patient-centered care and the need for ongoing monitoring and support. Don't forget to like, subscribe, and share your thoughts with us! If there are specific topics or cases you'd like us to cover in future episodes, reach out to us. Episode Highlights: Overview of MDS and its treatment landscape Case discussions on treatment decisions for anemia and disease progression Insights on the use of luspatercept and hypomethylating agents Management of side effects and the importance of patient education Listen us on: Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Thanks for tuning in! We are the Oncology Brothers. #MDS, #MyelodysplasticSyndrome, #HMAs, #HemeMalignancy, #OncologyBrothers

  ListenShow Notes
• 

  Oncology Brothers: Practice-Changing Cancer Discussions

  Title: Treatment Algorithm of Myelodysplastic Syndrome (MDS) in 2026 - Dr. Thomas LeBlanc

  Aug 10, 202628 min

  Welcome to the Oncology Brothers podcast! In this episode, we were joined by Thomas LeBlanc, MD MA , from the Duke Cancer Institute to discuss the treatment algorithm for myelodysplastic syndrome (MDS). We dived deep into the importance of risk stratification in MDS, exploring lower-risk, intermediate-risk, and higher-risk categories. Dr. LeBlanc shared insights on the role of next-generation sequencing (NGS) and the Revised International Prognostic Scoring System (IPSS-R) in guiding treatment decisions. Key topics included: Treatment options for lower-risk MDS, including the use of erythropoiesis-stimulating agents (ESAs) and luspatercept The significance of ring sideroblasts and del(5q) in treatment selection The management of anemia, thrombocytopenia, and neutropenia in MDS patients The emerging role of imetelstat for heavily transfusion-dependent patients and its unique side effects Join us as we unpacked the complexities of MDS treatment and emphasize the importance of personalized care for patients. Listen us on: Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more insightful discussions in oncology! #MDS, #MyelodysplasticSyndrome, #RiskStratification, #OncologyBrothers

  ListenShow Notes
• 

  Oncology Brothers: Practice-Changing Cancer Discussions

  Pancreatic Cancer Management - Partners in Practice with Dr. Tim Brown & Ms. Heather Klein

  Aug 6, 202619 min

  Join us in this insightful episode of our new series, Partners in Practice . We delved into the critical role of teamwork in cancer care, focusing on the treatment landscape of metastatic pancreatic cancer. In this episode, we were joined by Dr. Timothy Brown , a GI medical oncologist from UT Southwestern, and Ms. Heather Klein, a GI-focused nurse practitioner. Together, we explored the latest treatment options, including modified FOLFIRINOX , NALIRIFOX, gemcitabine with nab-paclitaxel , and the emerging role of novel therapies like RAS inhibitors . Key topics include: Overview of current treatment paradigms for metastatic pancreatic cancer Discussion of side effects and patient management strategies The importance of communication and collaboration within the oncology team Insights into the future of pancreatic cancer treatment and the potential of new therapies Whether you're a healthcare professional, a patient, or simply interested in oncology, this episode offers valuable perspectives on delivering compassionate and effective cancer care. Listen us on: Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #PancreaticCancer, #PartnersInPractice, #RASinhibitors,#OncologyBrothers

  ListenShow Notes
• 

  Oncology Brothers: Practice-Changing Cancer Discussions

  Treatment Algorithm of Late Relapsed/Refractory Multiple Myeloma (RRMM)

  Aug 3, 202624 min

  In this episode of the Oncology Brothers podcast, we dived deep into the complexities of late relapse refractory multiple myeloma treatment. Joined by Maximilian Merz, MD, a myeloma specialist from the Memorial Sloan Kettering Cancer Center, the discussion covered the evolving treatment landscape, including the use of CAR-T cell therapies, bispecific antibodies, and the importance of assessing BCMA expression. Key topics included: The current treatment algorithms for late relapse refractory multiple myeloma The significance of antigen expression in guiding treatment decisions The role of bispecific antibodies like teclistamab and talquetamab Managing side effects and improving patient quality of life The importance of collaboration between community hematologists and tertiary care centers Join us as we explored the latest advancements in myeloma treatment and the critical role of patient education and support in navigating this challenging disease. Don't forget to check out our previous episodes on newly diagnosed multiple myeloma and early relapse refractory disease! Listen us on: Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Subscribe for more insights and updates on oncology treatments! #MultipleMyeloma, #CART, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers

  ListenShow Notes

Recent guests on Oncology Brothers: Practice-Changing Cancer Discussions. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.